Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis

Arthritis, Rheumatoid Clinical Trial

Official title:

An Observational Study Within the CorEvitas Registry to Evaluate Safety and Effectiveness of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs (bDMARDs) in Japan Among Patients Treated for Moderately to Severely Active Rheumatoid Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05572567
• Other study ID #: A3921429
• Status: Completed
• Start date: October 10, 2022
• Est. completion date: October 10, 2022

Study information

• Verified date: June 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a secondary structured database observational study conducted in Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs, including tofacitinib, collected as part of the CorEvitas Japan RA Registry.

The data as of September 2022 will be used for this study. The study will include data from March 2016 to the latest data cut available in 2022 for both effectiveness and safety outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: October 10, 2022
• Est. primary completion date: October 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with Rheumatoid Arthritis (RA) according to the 1987 American College of Rheumatology (ACR) or the ACR/European Lead Against Rheumatism (EULAR) 2010 RA Classification Criteria;

• At least 18 years of age or older;

• Was / Must be prescribed or switching to the following eligible medication for the first time ever at the enrollment visit:

• csDMARD: methotrexate (closed in February 2018);

• Anti-TNF bDMARD: adalimumab (originator or biosimilar), certolizumab pegol, etanercept (originator or biosimilar), golimumab, infliximab (originator or biosimilar), or any other anti-TNF biosimilar approved during the study;

• Non-TNF bDMARD: abatacept, tocilizumab, sarilumab (closed in June 2020);

• JAK inhibitor: tofacitinib, baricitinib, peficitinib, filgotinib, upadacitinib.

Exclusion Criteria:

• Data that are prior to March 2016 and after June 2022

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid

Locations

Country	Name	City	State
Japan	Pfizer	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence rates of selected safety events of interest	Safety events of interest ie. total CVD, serious infections, total Herpes Zoster, and total malignancy excluding NMSC (non-melanoma skin cancer) in the Tofacitinib, non-TNF, anti-TNFi, and MTX cohorts by estimating marginal means of incidence rates of selected safety events of interest.	Index date, 90 days after the end of therapy or end of data collection
Secondary	Mean change from baseline to 6-months of CDAI	The Clinical Disease Activity Index(CDAI) is the sum of 4 outcome parameters: tender and swollen joint counts (28 joints assessed) and patient's and physician's global assessments of disease activity (on a 0-10-cm visual analog scale). Range of possible scores is 0-76.	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of J-HAQ	J-HAQ is Japanese version of the HAQ-DI. The Health Assessment Questionnaire-Disability Index (HAQ-DI) assesses the degree of difficulty a subject has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing "no difficulty," 1 as "some difficulty," 2 as "much difficulty," and 3 as "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of patient pain VAS	Patient pain VAS scale is measured on a visual analog scale ranging from 0 (no pain) to 100 mm (worst pain).	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of patient global assessment VAS	Patient global assessment VAS is measured on a visual analog scale ranging from 0 (no arthritis activity) to 100 mm (extremely active arthritis).	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of patient fatigue VAS	Patient fatigue VAS is measured on a visual analog scale ranging from 0 (no fatigue) to 100 mm (worst fatigue).	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of morning stiffness	Patient morning stiffness assesses the length of time of morning stiffness (in hours/minutes).	Index date, 6-month follow-up visit
Secondary	Mean change from baseline to 6-months of EA-5D-5L	The EQ 5D 5L is a validated health outcomes instrument that generates a simple descriptive profile on 5 domains of health. The domains are rated on 5 levels, and the instrument is composed of both a short, cognitively simple questionnaire and a VAS scale.	Index date, 6-month follow-up visit
Secondary	Achievement of minimally clinically important difference (MCID) at 6-month follow-up	Achievement of minimally clinically important difference (MCID) [4] at 6-month follow-up, based on the CDAI value at initiation. Specifically, MCID > 1 if CDAI at baseline is = 10, MCID > 6 if CDAI at baseline ranges between (10, 22], MCID > 12 if CDAI at baseline > 22.	6-month follow-up visit
Secondary	Modified ACR20/50/70	Modified ACR20/50/70 (mACR20/50/70), defined as 20/50/70% improvement in tender and swollen joint count, and 20/50/70% improvement in 2 of the following four domains at the 6-month follow-up visit: patient pain assessment, patient global assessment, physician global assessment, patient self-addressed disability, measured by the J-HAQ score.	6-month follow-up visit

External Links

•   To obtain contact information for a study center near you, click here.